$32.70 0.00 (%) NPS Pharmaceuticals Inc - NASDAQ

Sep. 11, 2014 | 04:00 PM

Partner Headlines

  1. US Stock Futures Flat Ahead Of Economic Data

    Benzinga | Sep. 12, 2014 | 07:40AM EST
  2. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara Biologics License Application

    Benzinga | Sep. 12, 2014 | 07:07AM EST
  3. FDA says NPS drug is effective

    IBD | Sep. 10, 2014 | 18:53PM EST
  4. Stocks Gain As Oil, Euro Continue Sharp Sell Off

    Benzinga | Sep. 10, 2014 | 17:09PM EST
  5. Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies Shares Slide

    Benzinga | Sep. 10, 2014 | 15:29PM EST
  6. U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

    Benzinga | Sep. 10, 2014 | 12:48PM EST
  7. Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

    Benzinga | Sep. 10, 2014 | 11:22AM EST
  8. Benzinga's Volume Movers

    Benzinga | Sep. 10, 2014 | 10:20AM EST
  9. Morning Market Movers

    Benzinga | Sep. 10, 2014 | 09:39AM EST
  10. FDA Posts Briefing Materials For Advisory Committee Meeting Reviewing Natpara For Hypoparathyroidism

    Benzinga | Sep. 10, 2014 | 08:07AM EST
  11. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)

    Benzinga | Aug. 4, 2014 | 08:13AM EST
  12. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD | Jun. 18, 2014 | 11:57AM EST
  13. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs Onto Gains

    Benzinga | May. 8, 2014 | 15:36PM EST
  14. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat Earnings; Tesla Shares Slide

    Benzinga | May. 8, 2014 | 13:11PM EST
  15. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats Street View

    Benzinga | May. 8, 2014 | 10:47AM EST
  16. Morning Market Losers

    Benzinga | May. 8, 2014 | 09:51AM EST
  17. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness

    Benzinga | Apr. 16, 2014 | 09:46AM EST
  18. Benzinga's Top Initiations

    Benzinga | Mar. 25, 2014 | 08:26AM EST
  19. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga | Feb. 19, 2014 | 10:30AM EST
  20. NPS Pharma Finds Big Success In Tiny Markets

    IBD | Feb. 13, 2014 | 18:15PM EST
  21. Market Wrap For January 8: Fed Minutes Released

    Benzinga | Jan. 8, 2014 | 16:39PM EST
  22. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara by EC

    Benzinga | Jan. 3, 2014 | 08:34AM EST
  23. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts | Nov. 7, 2013 | 12:54PM EST
  24. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain Down

    Benzinga | Nov. 6, 2013 | 15:41PM EST
  25. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term Use

    Benzinga | Oct. 14, 2013 | 08:04AM EST
  26. Mid-Afternoon Market Update: Markets Green as Spirit Airlines Soars

    Benzinga | Oct. 11, 2013 | 15:57PM EST
  27. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; SolarCity Spikes Higher

    Benzinga | Oct. 11, 2013 | 12:39PM EST
  28. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat Core Earnings

    Benzinga | Oct. 11, 2013 | 10:34AM EST
  29. Orphan Drugs: No (Payer) News Is Good News

    YCharts | Oct. 9, 2013 | 14:08PM EST
  30. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary Endpoint

    Benzinga | Oct. 7, 2013 | 08:09AM EST
  31. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals as Gattex and Natpara Could Provide Meaningful Annuities

    Benzinga | Oct. 3, 2013 | 10:17AM EST
  32. Benzinga's Top Initiations

    Benzinga | Oct. 3, 2013 | 07:29AM EST
  33. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows Sustained Effects

    Benzinga | Oct. 2, 2013 | 08:13AM EST
  34. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus | Sep. 29, 2013 | 14:43PM EST
  35. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals on Emerging Market Leader Status

    Benzinga | Sep. 20, 2013 | 10:39AM EST
  36. Benzinga's Top Initiations

    Benzinga | Sep. 20, 2013 | 07:48AM EST
  37. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following Gattex Survey

    Benzinga | Aug. 21, 2013 | 12:05PM EST
  38. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga | Aug. 9, 2013 | 16:35PM EST
  39. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It

    YCharts | Feb. 1, 2013 | 06:17AM EST
  40. You Can Expect More Insider Trading in Pharma Stocks: Here's Why

    YCharts | Dec. 28, 2012 | 04:47AM EST
  41. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga | Dec. 21, 2012 | 07:55AM EST
  42. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga | Dec. 21, 2012 | 04:58AM EST
  43. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short Bowel Syndrome Patients

    Benzinga | Nov. 29, 2012 | 01:25AM EST
  44. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 9, 2012 | 03:04AM EST
  45. Benzinga Mid-Afternoon Market Update

    Benzinga | Oct. 18, 2012 | 09:43AM EST
  46. Benzinga Mid-Day Market Update

    Benzinga | Oct. 18, 2012 | 06:45AM EST
  47. Benzinga Mid-Morning Market Update

    Benzinga | Oct. 18, 2012 | 04:50AM EST
  48. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

    Benzinga | Oct. 17, 2012 | 04:04AM EST
  49. FDA Advisory Committee Unanimously Recommends Approval of Gattex® (teduglutide) for Adults with Short Bowel Syndrome (SBS)

    Benzinga | Oct. 16, 2012 | 09:49AM EST
  50. Benzinga Mid-Day Market Update

    Benzinga | Oct. 16, 2012 | 07:40AM EST
Trading Center